Real-world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients with metastatic colorectal cancer.

Pham, Catherine; Niu, Fang; Delate, Thomas; L. Buchschacher, Gary; Li, Yan; Ekinci, Ekim; Le, Kim; L. Hui, Rita

doi:10.1200/jco.2022.40.16_suppl.3552

Public

Real-world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients with metastatic colorectal cancer.

Published in Journal of Clinical Oncology • Jun 1, 2022

Authors:

Catherine Pham

Fang Niu

Thomas Delate

Abstract

3552 Background: Bevacizumab-awwb was the first biosimilar approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer and became available for use in July 2019. Clinical comparative efficacy and safety of bevacizumab-awwb to bevacizumab was established in a single study of adult...

Subject

Bevacizumab

Medicine

Biosimilar

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!